Evidence map›Paper›PMID 42033519›Full record

ArticleDiscover oncology2026

In vitro evidence that perampanel modulates miR-21-5p and miR-29a-3p associated with anti-glioma effects.

Sara Donzelli, Giulia Orlandi, Marta Maschio, Annachiara D'Urso, Daniela Rutigliano, Serena Pellegatta, Giovanni Blandino, Andrea Salmaggi, Emilio Ciusani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sara DonzelliTranslational Oncology Research Unit, IRCCS Regina Elena National Cancer Institute, 00144, Rome, Italy.
Giulia OrlandiMicrobiology and Virology Unit, IRCCS San Gallicano Dermatological Institute, 00144, Rome, Italy.
Marta MaschioNeurorehabilitation Department, Villa delle Querce Clinic, Nemi, 00074, Rome, Italy.
Annachiara D'UrsoDepartment of Diagnostic and Technology, SSD Laboratory Medicine, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy.
Daniela RutiglianoTranslational Oncology Research Unit, IRCCS Regina Elena National Cancer Institute, 00144, Rome, Italy.
Serena PellegattaUnit of Immunotherapy of Brain Tumors, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy.
Giovanni BlandinoTranslational Oncology Research Unit, IRCCS Regina Elena National Cancer Institute, 00144, Rome, Italy.
Andrea SalmaggiDepartment of Neurosciences Neurology Unit, ASST Lecco, 23900, Lecco, Italy. andrea.salmaggi@gmail.com.
Emilio CiusaniDepartment of Diagnostic and Technology, SSD Laboratory Medicine, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy.

Funding

Ministero della Salute ricerca corrente
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

GliomamicroRNAPerampanelTumor-related epilepsy

Identifiers

PMID42033519
PMCPMC13481593

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.